lobbying_activities: 2377714

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2377714	f998f33b-26ff-432d-8a6e-bfa2c8144e71	Q4	CHRISTOPHER MOYER	401093053	CAMERON COMPANIES	2019	fourth_quarter	MMM	Monitored the introduction of drug pricing legislation (HR 3) for its potential impact on existing and emerging cancer drug therapies and site neutrality. Monitored Medicare reimbursement developments in the agencies and Congress for alternative cancer therapies, such as CAR-T. Reviewed HR 1948, Lymphedema Treatment Act and HR 3235, Access to Genetic Counselor Services Act for potential support.	HOUSE OF REPRESENTATIVES,SENATE	10000		0	0	2020-01-06T09:59:01.590000-05:00